公开(公告)号：US20220135550A1

公开(公告)日：2022-05-05

申请号：US17544490

申请日：2021-12-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dean A. WACKER ,  Susheel Jethanand NARA ,  Srinivas CHERUKU ,  Kandhasamy SARKUNAM ,  Firoz Ali JAIPURI ,  Soodamani THANGAVEL ,  Srinivas JOGI ,  Pavan Kalyan KATHI

IPC: C07D413/12 ,  A61P11/00 ,  C07D271/06

Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20170239249A1

公开(公告)日：2017-08-24

申请号：US15514728

申请日：2015-09-25

Applicant: Bristol-Myers Squibb Company

Inventor： Richard A. HARTZ ,  Vijay T. AHUJA ,  John E. MACOR ,  Joanne J. BRONSON ,  Bireshwar DASGUPTA ,  Carolyn Diane DZIERBA ,  Susheel Jethanand NARA ,  Maheswaran Sivasamban KARATHOLUVHU

IPC: A61K31/517

CPC classification number: A61K31/517

Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

公开(公告)号：US20210355113A1

公开(公告)日：2021-11-18

申请号：US17261968

申请日：2019-07-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron BALOG ,  Steven P. SEITZ ,  Jay A. MARKWALDER ,  David K. WILLIAMS ,  Weifang SHAN ,  Susheel Jethanand NARA ,  Saumya ROY ,  Srinivas CHERUKU ,  Nagalakshmi PULICHARLA

IPC: C07D405/14 ,  C07D405/10 ,  C07D413/14 ,  C07D313/08 ,  C07D413/10 ,  C07D417/14 ,  C07D307/79 ,  C07K16/28

Abstract: The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

公开(公告)号：US20210299126A1

公开(公告)日：2021-09-30

申请号：US17261954

申请日：2019-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron BALOG ,  Jay A. MARKWALDER ,  Weifang SHAN ,  David K. WILLIAMS ,  Susheel Jethanand NARA ,  Saumya ROY ,  Soodamani THANGAVEL ,  Srinivas CHERUKU ,  Ramesh Kumar SISTLA

IPC: A61K31/506 ,  A61K39/395 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D417/10 ,  C07D213/75 ,  C07D401/14 ,  A61K31/4439 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  C07D405/14 ,  C07D487/04 ,  C07D417/14 ,  A61K31/5377 ,  A61K31/4725 ,  C07D413/14 ,  C07D213/74

Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

公开(公告)号：US20210290613A1

公开(公告)日：2021-09-23

申请号：US16328449

申请日：2017-08-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Emily Charlotte CHERNEY ,  Weifang SHAN ,  Liping ZHANG ,  Susheel Jethanand NARA ,  Audris HUANG ,  James Aaron BALOG

IPC: A61K31/4709 ,  C07D401/08 ,  C07D491/056 ,  C07D471/04 ,  C07D417/12 ,  C07D401/12 ,  C07D413/12 ,  C07D487/04 ,  A61K31/517 ,  A61K31/5025 ,  A61K31/4375 ,  A61K39/395

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.